NasdaqGS:EIDX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Eidos Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EIDX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-14.5%

EIDX

-2.2%

US Biotechs

-0.8%

US Market


1 Year Return

23.0%

EIDX

35.6%

US Biotechs

13.8%

US Market

Return vs Industry: EIDX underperformed the US Biotechs industry which returned 35.6% over the past year.

Return vs Market: EIDX exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

EIDXIndustryMarket
7 Day-14.5%-2.2%-0.8%
30 Day6.9%-0.08%-5.0%
90 Day0.4%-1.7%10.1%
1 Year23.0%23.0%38.0%35.6%16.4%13.8%
3 Yearn/a15.6%10.0%36.9%27.8%
5 Yearn/a19.3%11.0%85.0%64.2%

Price Volatility Vs. Market

How volatile is Eidos Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eidos Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EIDX ($45.07) is trading below our estimate of fair value ($294.64)

Significantly Below Fair Value: EIDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EIDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: EIDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EIDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EIDX is overvalued based on its PB Ratio (11.6x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Eidos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-14.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EIDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EIDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EIDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EIDX's revenue (63.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: EIDX's revenue (63.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EIDX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Eidos Therapeutics performed over the past 5 years?

-44.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EIDX is currently unprofitable.

Growing Profit Margin: EIDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EIDX is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare EIDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EIDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: EIDX has a negative Return on Equity (-42.68%), as it is currently unprofitable.


Next Steps

Financial Health

How is Eidos Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: EIDX's short term assets ($178.8M) exceed its short term liabilities ($15.4M).

Long Term Liabilities: EIDX's short term assets ($178.8M) exceed its long term liabilities ($22.0M).


Debt to Equity History and Analysis

Debt Level: EIDX's debt to equity ratio (11.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EIDX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EIDX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EIDX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 43.8% each year.


Next Steps

Dividend

What is Eidos Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EIDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EIDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EIDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EIDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EIDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Neil Kumar (41 yo)

4.5yrs

Tenure

US$247,684

Compensation

Dr. Neil Kumar, Ph.D., is a co-Founder and has served as BridgeBio Pharma, Inc.’s Chief Executive Officer and a Member of Board of Directors since April 2015. He serves as Director of Phoenix Tissue Repair ...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD247.68K) is below average for companies of similar size in the US market ($USD4.61M).

Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Neil Kumar
CEO & Director4.5yrsUS$247.68kno data
Uma Sinha
Chief Scientific Officer & Director0.75yrUS$533.40k0.86%
$ 14.9m
Cameron Turtle
Chief Business Officer1.83yrsUS$578.40k0.18%
$ 3.2m
Jonathan Fox
President & Chief Medical Officer3.92yrsUS$1.71m0.99%
$ 17.2m
Isabella Graef
Co-Founder & Board Advisorno dataUS$150.00kno data
Mamoun Alhamadsheh
Co-Founderno datano datano data
Franco Valle
Senior VP of Finance0.67yrno data0.0011%
$ 20.0k
Matt Outen
Acting Chief Commercial Officerno datano datano data
Hoyoung Huh
Consultant1.75yrsUS$724.60kno data

2.9yrs

Average Tenure

51yo

Average Age

Experienced Management: EIDX's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Neil Kumar
CEO & Director4.5yrsUS$247.68kno data
Uma Sinha
Chief Scientific Officer & Director0.75yrUS$533.40k0.86%
$ 14.9m
Isabella Graef
Co-Founder & Board Advisorno dataUS$150.00kno data
Ali Satvat
Independent Director2.25yrsUS$473.91k0%
$ 0
Douglas Rohlen
Independent Director0.083yrno datano data
Suzanne Hooper
Independent Director0.083yrno datano data
William Lis
Independent Director1.75yrsUS$553.91k0%
$ 0

1.3yrs

Average Tenure

54yo

Average Age

Experienced Board: EIDX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

Eidos Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eidos Therapeutics, Inc.
  • Ticker: EIDX
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.738b
  • Shares outstanding: 38.57m
  • Website: https://www.eidostx.com

Number of Employees


Location

  • Eidos Therapeutics, Inc.
  • 101 Montgomery Street
  • Suite 2000
  • San Francisco
  • California
  • 94104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EIDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
6MXDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 05:50
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.